The Role of Statins in the Prevention of Ovarian and Endometrial Cancers.
Journal
Cancer prevention research (Philadelphia, Pa.)
ISSN: 1940-6215
Titre abrégé: Cancer Prev Res (Phila)
Pays: United States
ID NLM: 101479409
Informations de publication
Date de publication:
03 04 2023
03 04 2023
Historique:
received:
22
09
2022
revised:
05
12
2022
accepted:
13
02
2023
pmc-release:
03
04
2024
medline:
4
4
2023
entrez:
3
4
2023
pubmed:
4
4
2023
Statut:
ppublish
Résumé
Ovarian and endometrial cancers are the most common gynecologic malignancies and emerging evidence suggests that lipid metabolism and subsequent inflammation are important etiologic factors for both tumors. Statins (HMG-CoA reductase inhibitors) are the most widely prescribed lipid-lowering drugs in the United States and are used by 25% of adults aged 40+ years. In addition to their cardio-protective actions, statins have anti-inflammatory effects and have demonstrated antiproliferative and apoptotic properties in cancer cell lines, supporting a potential role in cancer prevention. To appropriately quantify potential public health impact of statin use for cancer prevention, there is a great need to understand the potential risk reduction among individuals at a higher risk of gynecologic cancers, the group that will likely need to be targeted to effectively balance risk/benefit of medications repurposed for cancer prevention. In this commentary, we focus on summarizing emerging evidence suggesting that the anti-inflammatory and lipid-lowering mechanisms of statins may provide important cancer-preventive benefits for gynecologic cancers as well as outline important unanswered questions and future research directions.
Identifiants
pubmed: 37009709
pii: 718839
doi: 10.1158/1940-6207.CAPR-22-0374
pmc: PMC10405632
mid: NIHMS1917390
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Lipids
0
Anti-Inflammatory Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
191-197Subventions
Organisme : Intramural NIH HHS
ID : Z01 CP010128
Pays : United States
Informations de copyright
©2023 American Association for Cancer Research.
Références
Nat Med. 2019 Oct;25(10):1601-1606
pubmed: 31591592
JAMA. 2022 Aug 23;328(8):746-753
pubmed: 35997723
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
JAMA Cardiol. 2017 Jan 1;2(1):66
pubmed: 27842172
Best Pract Res Clin Obstet Gynaecol. 2020 May;65:66-78
pubmed: 32107136
Int J Mol Sci. 2020 Jul 02;21(13):
pubmed: 32630698
J Clin Invest. 2002 Aug;110(3):285-8
pubmed: 12163444
Curr Epidemiol Rep. 2015 Dec;2(4):221-228
pubmed: 26954351
Clin Obstet Gynecol. 2017 Dec;60(4):738-757
pubmed: 28957949
J Am Coll Cardiol. 2018 Apr 24;71(16):1729-1737
pubmed: 29673463
Circ Cardiovasc Genet. 2014 Dec;7(6):955-964
pubmed: 25516625
Cancer Causes Control. 2020 Apr;31(4):309-320
pubmed: 32100190
Acta Obstet Gynecol Scand. 2020 Sep;99(9):1135-1146
pubmed: 32180221
Oncotarget. 2017 Jun 27;8(37):62425-62434
pubmed: 28977956
Int J Cancer. 2017 Feb 1;140(3):600-610
pubmed: 27770434
Front Oncol. 2021 Nov 11;11:761107
pubmed: 34858839
Cancer Res. 2019 Oct 15;79(20):5442-5451
pubmed: 31462430
Endocr Rev. 2020 Apr 1;41(2):
pubmed: 31512725
Trends Immunol. 2022 Jan;43(1):78-92
pubmed: 34942082
Clin Gastroenterol Hepatol. 2013 Feb;11(2):109-18; quiz e13-4
pubmed: 22982096
Gynecol Oncol. 2014 Jun;133(3):647-55
pubmed: 24736024
Cancer Res. 2020 Mar 15;80(6):1357-1367
pubmed: 31969373
Int J Cancer. 2021 Jan 15;148(2):307-319
pubmed: 32851660
J Fam Pract. 2019 Apr;68(3):146-151
pubmed: 31039213
Biochem Biophys Rep. 2015 Dec 03;5:127-133
pubmed: 28955814
BMC Cancer. 2019 Jul 24;19(1):730
pubmed: 31340777
Nat Rev Drug Discov. 2005 Dec;4(12):977-87
pubmed: 16341063
JAMA. 2020 Feb 18;323(7):646-655
pubmed: 32068819
Circulation. 2002 Apr 2;105(13):1531-3
pubmed: 11927515
PLoS One. 2006 Dec 20;1:e97
pubmed: 17183729
Nat Clin Pract Oncol. 2005 Feb;2(2):82-9
pubmed: 16264880
J Womens Health Gend Based Med. 2001 Dec;10(10):971-81
pubmed: 11788107
Clin Cancer Res. 2003 Jan;9(1):10-9
pubmed: 12538446
Cancer Causes Control. 2020 Oct;31(10):869-879
pubmed: 32685996
Gastroenterology. 2016 Jan;150(1):14-8
pubmed: 26602220
J Natl Cancer Inst. 2020 Jun 1;112(6):628-636
pubmed: 31593240
Clin Cancer Res. 2020 Nov 15;26(22):5791-5800
pubmed: 32887721
Eur J Obstet Gynecol Reprod Biol. 2022 Jan;268:74-81
pubmed: 34875557
Cancer Epidemiol Biomarkers Prev. 2021 Nov;30(11):2044-2051
pubmed: 34404683